Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J J Sramek

Showing results (31-40 of 105) with videos related to

Pageof 11
Sort By:
Clinical Therapeutics|May 1, 1997
Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxietyJ J Sramek, E J Frackiewicz, N R Cutler
The Annals of Pharmacotherapy|May 20, 1999
Cholinesterase inhibitors: a therapeutic strategy for Alzheimer diseaseW J Krall, J J Sramek, N R Cutler
The Western Journal of Medicine|August 1, 1982
'Loads' alertA M Khajawall, J J Sramek, G M Simpson
The Annals of Pharmacotherapy|February 26, 1998
Potential for adverse events in patients with generalized anxiety disorderE J Frackiewicz-Koziol, J J Sramek, N R Cutler
DICP : the Annals of Pharmacotherapy|January 1, 1990
Patterns of neuroleptic usage in continuously hospitalized chronic schizophrenic patients: evidence for development of drug toleranceJ J Sramek, V Gaurano, J M Herrera, et al.
Life Sciences|April 21, 1999
NXX-066 in patients with Alzheimer's disease: a bridging studyJ J Sramek, J Hourani, S S Jhee, et al.
Journal of Clinical Psychopharmacology|February 1, 1995
Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorderJ J Sramek, R E Robinson, A Suri, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 1, 1995
The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's diseaseJ J Sramek, N R Cutler, D J Hurley, et al.
Anxiety|January 1, 1994
Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findingsJ J Sramek, M S Kramer, S A Reines, et al.
The Annals of Pharmacotherapy|September 1, 1992
Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's diseaseN R Cutler, J J Sramek, M F Murphy, et al.
Pageof 11

Showing results (31-40 of 105) with videos related to

Sort By:
Pageof 11
Clinical Therapeutics|May 1, 1997
Efficacy and safety of two dosing regimens of buspirone in the treatment of outpatients with persistent anxietyJ J Sramek, E J Frackiewicz, N R Cutler
The Annals of Pharmacotherapy|May 20, 1999
Cholinesterase inhibitors: a therapeutic strategy for Alzheimer diseaseW J Krall, J J Sramek, N R Cutler
The Western Journal of Medicine|August 1, 1982
'Loads' alertA M Khajawall, J J Sramek, G M Simpson
The Annals of Pharmacotherapy|February 26, 1998
Potential for adverse events in patients with generalized anxiety disorderE J Frackiewicz-Koziol, J J Sramek, N R Cutler
DICP : the Annals of Pharmacotherapy|January 1, 1990
Patterns of neuroleptic usage in continuously hospitalized chronic schizophrenic patients: evidence for development of drug toleranceJ J Sramek, V Gaurano, J M Herrera, et al.
Life Sciences|April 21, 1999
NXX-066 in patients with Alzheimer's disease: a bridging studyJ J Sramek, J Hourani, S S Jhee, et al.
Journal of Clinical Psychopharmacology|February 1, 1995
Efficacy trial of the 5-HT2 antagonist MDL 11,939 in patients with generalized anxiety disorderJ J Sramek, R E Robinson, A Suri, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|January 1, 1995
The utility of salivary amylase as an evaluation of M3 muscarinic agonist activity in Alzheimer's diseaseJ J Sramek, N R Cutler, D J Hurley, et al.
Anxiety|January 1, 1994
Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findingsJ J Sramek, M S Kramer, S A Reines, et al.
The Annals of Pharmacotherapy|September 1, 1992
Implications of the study population in the early evaluation of anticholinesterase inhibitors for Alzheimer's diseaseN R Cutler, J J Sramek, M F Murphy, et al.
Pageof 11